FindTrial
Sign In

Studying the Use of Chemotherapy Before Surgery for Eye Surface Tumors

Role of Neoadjuvant Chemotherapy in Ocular surface Squamous Neoplasia - A Prospective Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/097969
Enrollment
10
Registered
2025-11-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H118- Other specified disorders of conjunctiva

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Dr Purnamita Saras Dr Rajendra Prasad Centre for Ophthalmic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All cases of biopsy proven Ocular Squamous Surface Neoplasia (OSSN) with tumor stage T3 with eyelid involvement, fornix involvement, corneal involvement more than 50 percent and not responding to topical treatment, intraocular extension. Tumors with nodal involvement, stage N1 and Patients consenting for Neoadjuvant Chemotherapy (NACT)

Exclusion criteria

Exclusion criteria: Patient not consenting for NACT Patient not fit to receive NACT Hematogenous metastasis (any M1)

Design outcomes

Primary

MeasureTime frame
To study the tumor response to Neoadjuvant Chemotherapy in cases of surgically challenging OSSNTimepoint: 12 months—

Secondary

MeasureTime frame
To study the histopathological features of chemo-reduced tumor Timepoint: total study duration - 18 months;To study chemo-toxicity profile of the drugs in NACT regimenTimepoint: Total study duration- 18 months—

Countries

India

Contacts

Public ContactRachna Meel

Dr. Rajendra Prasad Centre for Ophthalmic Sciences

dr.rachnameel@gmail.com9868846891

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026